CA2589765C — Compounds for inhibition of chymotrypsin-like activity of the 20s proteasome
Assigned to Onyx Therapeutics Inc · Expires 2015-06-30 · 11y expired
What this patent protects
A compound having a structure of formula I or a pharmaceutically acceptable salt thereof, (see formula I) wherein X is O; Y is NH, N-alkyl, or O; Z is O or C(R9)2; R1, R2, R3, and R4 are all hydrogen; each R5, R6, R7, R8, and R9 is independently selected from hydrogen, C1-6alkyl,…
USPTO Abstract
A compound having a structure of formula I or a pharmaceutically acceptable salt thereof, (see formula I) wherein X is O; Y is NH, N-alkyl, or O; Z is O or C(R9)2; R1, R2, R3, and R4 are all hydrogen; each R5, R6, R7, R8, and R9 is independently selected from hydrogen, C1-6alkyl, C1-6hydroxyalkyl, C1-6alkoxyalkyl, aryl, and C1-6aralkyl, each of which is optionally substituted with a group selected from alkyl, amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether; m is an integer from 0 to 2; and n is an integer from 0 to 2. The invention also relates to uses of such compounds for the inhibition of chymotrypsin-like activity of a 20S-proteasome.
Drugs covered by this patent
- Kyprolis (carfilzomib) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.